AC Immune (ACIU) Receivables - Net (2014 - 2026)

AC Immune (ACIU) posted quarterly Receivables - Net of $28.4 million for Q3 2024, down 99.83% quarter-over-quarter from $16.7 billion in Q4 2023.

AC Immune (ACIU) Receivables - Net (2014 - 2026) Analysis & Trends

AC Immune (ACIU) has reported Receivables - Net for 10 consecutive years, with $28.4 million the latest figure, recorded in Q3 2024.

In Q3 2024, Receivables - Net changed N/A year-over-year to $28.4 million; the TTM figure through Sep 2024 stood at $28.4 million (changed N/A YoY), while the FY2023 annual figure was $16.7 billion, changed N/A from the prior year.
Receivables - Net eased to $28.4 million in Q3 2024 per ACIU's latest filing, from $16.7 billion in the prior quarter.
Across five years, Receivables - Net topped out at $16.7 billion in Q4 2023 and bottomed at $7.5 million in Q4 2021.
Historically, Receivables - Net has averaged $3.4 billion across 4 years, with a median of $62.0 million in 2020.
Annual changes were most pronounced in 2020 — Receivables - Net soared 21507.65% — and 2021, when it slumped 88.73%.
AC Immune's Receivables - Net stood at $66.4 million in 2020, then plunged by 88.73% to $7.5 million in 2021, then jumped by 222868.09% to $16.7 billion in 2023, then slumped by 99.83% to $28.4 million in 2024.
Business Quant data shows ACIU's Receivables - Net at $28.4 million in Q3 2024, $16.7 billion in Q4 2023, and $7.5 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	AC Immune	253.89 Mn	253.89 Mn	-

Download Data